Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiencyPR Newswire May 22
PHILADELPHIA, May 22, 2013 /PRNewswire/ -- Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN © -C (Alpha 1 -Proteinase ...
Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™Business Wire May 21
Grifols, S.A. and Aradigm Corporation today announced the signing of an exclusive, worldwide license for Aradigm’s proprietary formulations of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis .
TheStreet Ratings group highlights 3 stocks pushing the drugs industry higher today.